Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX3FN4)

Drug Name

ISIS-APOCIII Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Atherosclerosis	BD40	Phase 1	[1]
Hyperlipemia	5C80	Phase 1	[1]
Inflammation	1A00-CA43.1	Phase 1	[1]
Metabolic syndrome x	5C50-5D2Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting ApoC-III messenger RNA (APOC3 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Volanesorsen	DM1YEPS	Hypertriglyceridemia	5C80.1	Approved	[2]
ARO-APOC3	DMABKHH	Familial chylomicronemia syndrome	5C80	Phase 3	[3]
Olezarsen	DMNLSFN	Familial chylomicronemia syndrome	5C80	Phase 3	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ApoC-III messenger RNA (APOC3 mRNA)	TTXOZQ1	APOC3_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
2	Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173.
3	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Curr Atheroscler Rep. 2021 Mar 10;23(5):20.
4	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 6;43(14):1401-1412.